RPRX Royalty Pharma plc
Research report · from SEC EDGAR
executive summary
Royalty Pharma plc (RPRX). Revenue is $2.38B (+5.1% y/y) at a 32% net margin. It is profitable. Our health score is B (76/100). No major red flags on file. Held by 1 tracked funds. It funds itself; low dilution risk.
Revenue (FY)
$2.38B
+5.1% y/y
✓ No major red flags from our filing-based checks.
who's buying
Insider buys / sells
0 / 10
Cash & ST investments
$586.4M
Operating cash flow
$2.49B
Dilution shelf
active shelf
Assembled from SEC EDGAR (XBRL, Form 4, 13F, filings), STOCK Act disclosures, and end-of-day prices — every figure is real and sourced; nothing is fabricated or predicted. Filings lag 40–90 days. Educational, not investment advice. Generated today by stocktools.ai.